{"id":"https://openalex.org/W2017672736","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.136","title":"Annualized Relapse Rate of First-Line Treatments for Multiple Sclerosis: A Meta-Analysis, Including Indirect Comparisons Versus Fingolimod (P01.136)","display_name":"Annualized Relapse Rate of First-Line Treatments for Multiple Sclerosis: A Meta-Analysis, Including Indirect Comparisons Versus Fingolimod (P01.136)","alternate_titles":[],"publication_year":2012,"publication_date":"2012-04-22","ids":{"openalex":"https://openalex.org/W2017672736","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.136","mag":"2017672736"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.78.1_meetingabstracts.p01.136","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.136","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.136","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2017672736"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005255068","display_name":"David Tyas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129647","display_name":"Novartis (United Kingdom)","ror":"https://ror.org/039s6n838","country_code":"GB","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210129647"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D. Tyas","raw_affiliation_strings":["Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom","institution_ids":["https://openalex.org/I4210129647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068567904","display_name":"Neil Roskell","orcid":"https://orcid.org/0000-0002-0751-259X","observed_orcids":["https://orcid.org/0000-0002-0751-259X"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Roskell","raw_affiliation_strings":["RTI Health Solutions Manchester"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions Manchester","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036989191","display_name":"Evelina A. Zimovetz","orcid":"https://orcid.org/0000-0002-8939-7838","observed_orcids":["https://orcid.org/0000-0002-8939-7838"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Zimovetz","raw_affiliation_strings":["RTI Health Solutions Manchester  United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions Manchester  United Kingdom","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030941835","display_name":"Catherine E. Rycroft","orcid":"https://orcid.org/0000-0001-8650-7205","observed_orcids":["https://orcid.org/0000-0001-8650-7205"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. Rycroft","raw_affiliation_strings":["RTI Health Solutions Manchester  United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions Manchester  United Kingdom","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111602325","display_name":"B. Eckert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B. Eckert","raw_affiliation_strings":["Novartis, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis, Cambridge, MA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"Meeting Abstracts 1","first_page":"P01.136","last_page":"P01.136"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.972000002861023},{"id":"https://openalex.org/keywords/annualized-relapse-rate","display_name":"annualized relapse rate","score":0.9670000076293945},{"id":"https://openalex.org/keywords/fingolimod","display_name":"fingolimod","score":0.984000027179718},{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.8659999966621399},{"id":"https://openalex.org/keywords/glatiramer-acetate","display_name":"glatiramer acetate","score":0.9909999966621399},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.8740000128746033},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8970000147819519},{"id":"https://openalex.org/keywords/indirect-comparison","display_name":"indirect comparison","score":0.7549999952316284},{"id":"https://openalex.org/keywords/network-meta-analysis","display_name":"network meta-analysis","score":0.824999988079071},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.8040000200271606},{"id":"https://openalex.org/keywords/interferon-beta-1a","display_name":"interferon beta-1a","score":0.7889999747276306},{"id":"https://openalex.org/keywords/interferon-beta-1b","display_name":"interferon beta-1b","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-heterogeneity","display_name":"treatment effect heterogeneity","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C2776036978","wikidata":"https://www.wikidata.org/wiki/Q425137","display_name":"Fingolimod","level":3,"score":0.9768328070640564},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7633819580078125},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5344312191009521},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.43937310576438904},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4187834858894348},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.12652957439422607}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.78.1_meetingabstracts.p01.136","doi":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.136","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.136","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2093046600","https://openalex.org/W1599202679","https://openalex.org/W2138992948","https://openalex.org/W2029064702","https://openalex.org/W2397308456","https://openalex.org/W7130820411","https://openalex.org/W2469254996","https://openalex.org/W4391367233","https://openalex.org/W2075936324","https://openalex.org/W34156660"],"abstract_inverted_index":{"Objective:":[0],"To":[2],"conduct":[3],"an":[4,300,315,342,354],"indirect":[5],"comparison":[6,134],"of":[7,41,88,102,166,193,206,212],"annualized":[8],"relapse":[9,246,273],"rates":[10],"(ARR)":[11],"for":[12,118,163,198,220,261,295,308,323,335,350],"fingolimod,":[13,89],"interferon":[14,90,92,171,175,179,183,262],"beta,":[15],"and":[16,29,39,57,74,120,136,161,187,224,264,282],"glatiramer":[17,95,167,265],"acetate":[18,96,168,266],"in":[19,43,97,106,227,248],"relapsing-remitting":[20],"multiple":[21],"sclerosis":[22],"(RRMS)":[23],"using":[24,111],"evidence":[25,127],"from":[26,48,55,152,276],"both":[27],"placebo-controlled":[28,50],"head-to-head":[30,56],"studies.":[31,59,284],"Background":[34],"Previous":[36],"systematic":[37,65,278],"reviews":[38],"meta-analyses":[40,154],"treatments":[42],"RRMS":[44,98,251],"derived":[45],"their":[46],"findings":[47,275],"either":[49],"studies":[51,79],"only":[52],"or":[53,86,94],"separately":[54],"comparative":[58,280],"Design/Methods:":[62],"A":[64],"literature":[66],"review":[67],"was":[68,109,124,129,138],"conducted":[69],"by":[70,115],"searching":[71],"MEDLINE,":[72],"EMBASE,":[73],"the":[75,107,112,116,164,194,225,231,272],"Cochrane":[76],"Library.":[77],"Included":[78],"were":[80,155,269],"randomized":[81],"controlled":[82],"trials":[83,104],"evaluating":[84],"one":[85],"more":[87],"beta-1a,":[91],"beta-1b,":[93],"populations.":[99],"The":[100,126,148,209,238,259],"quality":[101],"all":[103,254],"included":[105,232],"meta-analysis":[108],"assessed":[110],"criteria":[113],"recommended":[114],"Centre":[117],"Reviews":[119],"Dissemination.":[121],"Primary":[122],"outcome":[123,228],"ARR.":[125],"synthesis":[128],"performed":[130],"within":[131],"a":[132,141],"mixed-treatment":[133],"framework":[135],"ARR":[137],"analyzed":[139],"as":[140,299,314,341],"Poisson":[142],"outcome.":[143],"Results:":[146],"relative":[149],"ARRs":[150],"estimated":[151],"our":[153],"1.43,":[156],"1.51,":[157],"1.55,":[158],"1.67,":[159],"1.93,":[160],"2.32":[162],"comparisons":[165],"20":[169],"mg,":[170],"beta-1b":[172],"250":[173],"mcg,":[174,178,182,186],"beta-1a":[176,180,184],"44":[177],"22":[181],"30":[185],"placebo,":[188],"respectively,":[189],"versus":[190],"fingolimod.":[191],"None":[192],"95%":[195],"confidence":[196],"intervals":[197],"these":[199,207],"estimates":[200],"overlapped":[201],"unity,":[202],"implying":[203],"statistical":[204],"significance":[205],"findings.":[208],"key":[210],"limitations":[211],"this":[213],"study":[214],"are":[215],"heterogeneity":[216],"even":[217],"after":[218],"adjusting":[219],"population-level":[221],"baseline":[222],"characteristics":[223],"variability":[226],"definition":[229],"across":[230],"trials.":[233],"Conclusions:":[236],"MTC":[239],"results":[240,260],"suggest":[241],"that":[242],"fingolimod":[243],"significantly":[244],"reduces":[245],"frequency":[247],"patients":[249],"with":[250,253,271,297,310,325,337,352],"compared":[252],"current":[255],"first-line":[256],"disease-modifying":[257,267],"therapies.":[258],"beta":[263],"therapies":[268],"consistent":[270],"reduction":[274],"earlier":[277],"reviews,":[279],"trials,":[281],"real-world":[283],"Disclosure:":[287],"Dr.":[289,344],"Tyas":[290],"has":[291,304,319,331,346],"received":[292,305,320,332,347],"personal":[293,306,321,333,348],"compensation":[294,307,322,334,349],"activities":[296,309,324,336,351],"Novartis":[298],"employee.":[301,316,343,355],"Mr.":[302],"Roskell":[303],"RTI":[311,326,338],"Health":[312,339],"Solutions":[313,340],"Ms.":[317,329],"Zimovetz":[318],"Healh":[327],"Solutions.":[328],"Rycroft":[330],"Eckert":[345],"Novartisas":[353]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2017672736","counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
